This is a scientific validation event for a pre-revenue micro-cap with no financial data. The stock may see speculative interest given the EUROTOX presentation and FDA NAM momentum narrative, but the lack of revenue, contracts, or guidance means any move is purely sentiment-driven. Monitor for any subsequent commercial partnership announcements or revenue guidance in future filings.
Price Chart
Executive Summary
VivoSim Labs presented new clinical benchmark data at EUROTOX 2026 demonstrating its NAMkind™ 3D human liver and intestinal platforms' ability to predict drug toxicity for small molecules and ADCs. The data showed the platform could rank clinical safety risks and distinguish payload- and linker-dependent toxicities, including identifying trastuzumab deruxtecan as more hepatotoxic than trastuzumab emtansine. This is a scientific validation milestone for a pre-revenue micro-cap with no financial data disclosed, positioning the company in the growing NAM market but lacking any revenue, earnings, or commercial contracts to substantiate the narrative.
Key Facts
- VivoSim presented data at EUROTOX 2026 showing its NAMkind™ platform can predict drug toxicity for small molecules and ADCs.
- The NAMkind™ Liver platform ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine.
- The NAMkind™ Intestine model identified mucosal barrier deterioration before overt cytotoxicity, with human ileum more sensitive than colon.
- No financial data, revenue, earnings, guidance, or commercial contracts were disclosed in the press release.
- Market cap is $5M; the company is pre-revenue with no analyst bullish ratings and minimal insider buying ($3K in 30 days).
Financial Impact
No financial data disclosed; pre-revenue micro-cap with $5M market cap.
Risk Factors
- No revenue or commercial contracts disclosed; company is pre-revenue with $5M market cap.
- Forward-looking statements about regulatory tailwinds and platform adoption are unsubstantiated by hard financial data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363138 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $0.1575 $0.1520 | ▲ +3.49% | ▲ +3.35% | $0.1500 (+4.76%) |
Oct 6, 2026 20d ago | 8-K | $0.1915 $0.1609 | ▼ −15.98% | ▼ −15.00% | $0.1500 (−21.67%) |
Sep 16, 2026 5w ago | Press Release | $0.2621 $0.2291 | ▼ −12.59% | ▼ −15.15% | $0.1500 (−42.77%) |
Aug 11, 2026 10w ago | EFFECT | $0.3526 $0.2786 | ▲ +20.99% | ▲ +20.58% | $0.1500 (+57.46%) |
Aug 6, 2026 11w ago | 8-K | $0.3299 $0.3281 | ▼ −0.55% | ▼ −1.76% | $0.1500 (−54.53%) |
Jul 17, 2026 14w ago | 8-K | $0.5790 $0.4500 | ▲ +22.28% | ▲ +21.59% | $0.1500 (+74.09%) |
Apr 3, 2026 29w ago | 8-K | $1.71 $1.44 | ▼ −15.79% | ▼ −19.92% | $0.1500 (−91.23%) |
Apr 1, 2026 29w ago | Press Release | $1.62 $1.53 | ▲ +5.56% | ▲ +9.32% | $0.1500 (+90.74%) |
Apr 1, 2026 29w ago | EFFECT | $1.62 $1.53 | ▼ −5.56% | ▼ −9.32% | $0.1500 (−90.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers